These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33447638)

  • 21. Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence.
    Abuogi LL; Castillo-Mancilla J; Hampanda K; Owuor K; Odwar T; Onono M; Helova A; Turan JM; Anderson PL
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):310-317. PubMed ID: 34889866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acceptability and Feasibility of Providing Adherence Feedback Based on Tenofovir Diphosphate in Dried Blood Spots: Results from a Pilot Study Among Patients and Providers in Cape Town, South Africa.
    Ferraris CM; D'avanzo PA; Jennings L; Robbins RN; Nguyen N; Leu CS; Dolezal C; Mgbako O; Hsiao NY; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Belaunzarán-Zamudio PF; Mellins CA; Orrell C; Remien RH
    AIDS Behav; 2023 Oct; 27(10):3478-3486. PubMed ID: 37043053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
    Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
    AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L; Niu X; Brunelli MK; Mugwanya KK
    Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.
    Coyle RP; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR
    J Antimicrob Chemother; 2020 Jun; 75(6):1591-1598. PubMed ID: 32211787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
    Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
    Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM;
    J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; MaWhinney S
    Open Forum Infect Dis; 2021 Sep; 8(9):ofab463. PubMed ID: 34584902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.
    Seifert SM; Castillo-Mancilla JR; Erlandson K; Morrow M; Gandhi M; Kuncze K; Horng H; Zheng JH; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):295-298. PubMed ID: 29189417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.
    Mann SC; Morrow M; Coyle RP; Coleman SS; Saderup A; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):483-488. PubMed ID: 33136749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    van Heerden JK; Meintjes G; Barr D; Zhao Y; Griesel R; Keene CM; Wiesner L; Galileya LT; Denti P; Maartens G
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):260-267. PubMed ID: 38408216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women.
    Pyra M; Anderson P; Haberer JE; Heffron R; Celum C; Asiimwe S; Katabira E; Mugo NR; Bukusi EA; Baeten JM
    Front Pharmacol; 2019; 10():401. PubMed ID: 31057407
    [No Abstract]   [Full Text] [Related]  

  • 37. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression.
    Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A
    AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
    Coyle RP; Schneck CD; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL; Castillo-Mancilla JR
    AIDS Behav; 2019 Dec; 23(12):3493-3502. PubMed ID: 30798457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
    Tsuchiya K; Hayashi Y; Ryu S; Tran HT; Takano M; Tanaka K; Mizushima D; Oka S; Gatanaga H; Hamada A
    J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.